Krishna Institute of Medical Sciences Ltd.
KIMSHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
20 transcript(s)/analyst meet(s) served; 4 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 20 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| COVER_LETTER | 20210811 | 2021-06-30 | no | |
| COVER_LETTER | 20211112 | 2021-09-30 | no | |
| TRANSCRIPT | 20220524 | 2022-03-31 | yes | |
| COVER_LETTER | 20220812 | 2022-06-30 | no | |
| TRANSCRIPT | 20220818 | 2022-06-30 | yes | |
| COVER_LETTER | 20221112 | 2022-09-30 | no | |
| TRANSCRIPT | 20221117 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230215 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230525 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230811 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231110 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240208 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240523 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240814 | 2024-06-30 | yes | |
| TRANSCRIPT | 20250213 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250813 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251114 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260213 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260522 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260808 | 2026-06-30 | yes |
KIMS
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
The closes are adjusted for every split and bonus on record inside the period this series covers, and each adjustment is checked against the price move on its ex-date.
| Last close | 800.45 |
| 52-week range | 582.1 – 850.65 |
| Return 1M | 3.62% |
| Return 3M | 0.64% |
| Return 1Y | 10.19% |
| Return 3Y | 103.02% |
| Return 5Y | 227.02% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 1,180.00 |
| Other income | 16.00 |
| Total income | 1,196.00 |
| Cost of materials consumed | 0.00 |
| Purchases of stock-in-trade | 261.00 |
| Changes in inventories | -16.00 |
| Employee benefit expense | 213.00 |
| Finance costs | 83.00 |
Ownership — 2026-06-30, and the change from 2026-06-19
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.33 | 0.00 |
| institutions foreign | 0.15 | 0.00 |
| institutions domestic | 0.34 | -0.00 |
| mutual funds | 0.29 | -0.00 |
| public | 0.68 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| COVER_LETTER | 2022-09-30 | 4 |
| TRANSCRIPT | 2026-06-30 | 16 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 496.00 | 564.00 | 562.00 | 576.00 | 606.00 | 652.00 | 606.00 | 634.00 | 688.00 | 777.00 | 772.00 | 872.00 | 961.00 | 998.00 | 1,075.00 | 1,180.00 |
| Other income | 5.00 | 9.00 | 6.00 | 5.00 | 3.00 | 3.00 | 3.00 | 4.00 | 5.00 | 5.00 | 18.00 | 7.00 | 4.00 | 5.00 | 10.00 | 16.00 |
| Total income | 501.00 | 573.00 | 569.00 | 581.00 | 609.00 | 655.00 | 609.00 | 638.00 | 693.00 | 782.00 | 790.00 | 879.00 | 965.00 | 1,003.00 | 1,084.00 | 1,196.00 |
| Cost of materials consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of stock-in-trade | 113.00 | 118.00 | 124.00 | 119.00 | 135.00 | 143.00 | 124.00 | 135.00 | 145.00 | 157.00 | 170.00 | 192.00 | 204.00 | 211.00 | 235.00 | 261.00 |
| Changes in inventories | -3.00 | 7.00 | -1.00 | 3.00 | -5.00 | -2.00 | 1.00 | -1.00 | -2.00 | -1.00 | -8.00 | -8.00 | -8.00 | -14.00 | -3.00 | -16.00 |
| Employee benefit expense | 83.00 | 84.00 | 87.00 | 92.00 | 104.00 | 106.00 | 104.00 | 109.00 | 119.00 | 119.00 | 128.00 | 151.00 | 174.00 | 176.00 | 180.00 | 213.00 |
| Finance costs | 6.00 | 8.00 | 12.00 | 5.00 | 9.00 | 9.00 | 12.00 | 16.00 | 18.00 | 20.00 | 26.00 | 33.00 | 45.00 | 57.00 | 68.00 | 83.00 |
| Depreciation and amortisation | 29.00 | 31.00 | 33.00 | 35.00 | 32.00 | 33.00 | 35.00 | 46.00 | 39.00 | 41.00 | 45.00 | 53.00 | 66.00 | 79.00 | 85.00 | 101.00 |
| Other expenses | 165.00 | 202.00 | 200.00 | 199.00 | 215.00 | 229.00 | 229.00 | 232.00 | 248.00 | 284.00 | 296.00 | 344.00 | 387.00 | 426.00 | 455.00 | 499.00 |
| Total expenses | 393.00 | 451.00 | 456.00 | 454.00 | 491.00 | 517.00 | 507.00 | 537.00 | 566.00 | 620.00 | 656.00 | 765.00 | 868.00 | 934.00 | 1,021.00 | 1,140.00 |
| Profit before exceptional items and tax | 107.00 | 123.00 | 113.00 | 127.00 | 119.00 | 139.00 | 103.00 | 100.00 | 127.00 | 162.00 | 135.00 | 114.00 | 97.00 | 69.00 | 63.00 | 56.00 |
| Exceptional items | 0.00 | 15.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | -11.00 | 0.00 |
| Profit before tax | 107.00 | 137.00 | 113.00 | 127.00 | 119.00 | 139.00 | 103.00 | 100.00 | 127.00 | 162.00 | 135.00 | 114.00 | 97.00 | 69.00 | 52.00 | 56.00 |
| Current tax | 26.00 | 33.00 | 28.00 | 30.00 | 32.00 | 37.00 | 22.00 | 29.00 | 34.00 | 45.00 | 35.00 | 32.00 | 38.00 | 33.00 | 35.00 | 34.00 |
| Deferred tax | 2.00 | -1.00 | 3.00 | -1.00 | 0.00 | 0.00 | 4.00 | -0.00 | -2.00 | -4.00 | 7.00 | -4.00 | -13.00 | -16.00 | -13.00 | -15.00 |
| Tax expense | 28.00 | 31.00 | 31.00 | 29.00 | 32.00 | 37.00 | 26.00 | 29.00 | 32.00 | 42.00 | 42.00 | 29.00 | 25.00 | 17.00 | 22.00 | 19.00 |
| Profit for the period | 79.00 | 106.00 | 82.00 | 99.00 | 87.00 | 101.00 | 77.00 | 71.00 | 95.00 | 121.00 | 92.00 | 85.00 | 72.00 | 52.00 | 33.00 | 37.00 |
| Profit attributable to owners | 70.00 | 97.00 | 76.00 | 93.00 | 81.00 | 92.00 | 72.00 | 65.00 | 87.00 | 107.00 | — | 79.00 | 67.00 | 53.00 | 42.00 | 42.00 |
| Profit attributable to non-controlling interests | 9.00 | 9.00 | 6.00 | 5.00 | 6.00 | 9.00 | 5.00 | 6.00 | 9.00 | 13.00 | — | 6.00 | 5.00 | -2.00 | -9.00 | -4.00 |
| Other comprehensive income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | -2.00 | -1.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total comprehensive income | 80.00 | 106.00 | 82.00 | 99.00 | 87.00 | 101.00 | 77.00 | 71.00 | 95.00 | 118.00 | 92.00 | 84.00 | 72.00 | 52.00 | 34.00 | 37.00 |
| Earnings per share, basic | 8.74 | 12.13 | 9.49 | 11.65 | 10.10 | 11.50 | 8.98 | 8.18 | 10.82 | 2.68 | 2.22 | 1.96 | 1.67 | 1.33 | 1.06 | 1.04 |
| Earnings per share, diluted | 8.74 | 12.13 | 9.49 | 11.65 | 10.10 | 11.50 | 8.98 | 8.18 | 10.82 | 2.68 | 2.22 | 1.96 | 1.67 | 1.33 | 1.06 | 1.04 |
Annual results, as filed
| Line | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2026-03-31 |
|---|---|---|---|---|---|
| Revenue from operations | 1,330.00 | 1,651.00 | 2,198.00 | 2,498.00 | 3,905.00 |
| Other income | 10.00 | 20.00 | 26.00 | 13.00 | 26.00 |
| Total income | 1,340.00 | 1,671.00 | 2,224.00 | 2,511.00 | 3,931.00 |
| Cost of materials consumed | 283.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of stock-in-trade | 0.00 | 367.00 | 474.00 | 537.00 | 842.00 |
| Changes in inventories | 6.00 | -12.00 | 6.00 | -7.00 | -33.00 |
| Employee benefit expense | 220.00 | 262.00 | 346.00 | 422.00 | 682.00 |
| Finance costs | 32.00 | 16.00 | 31.00 | 47.00 | 202.00 |
| Depreciation and amortisation | 70.00 | 73.00 | 129.00 | 147.00 | 283.00 |
| Other expenses | 450.00 | 518.00 | 767.00 | 905.00 | 1,612.00 |
| Total expenses | 1,061.00 | 1,224.00 | 1,753.00 | 2,051.00 | 3,588.00 |
| Profit before exceptional items and tax | 279.00 | 447.00 | 470.00 | 460.00 | 342.00 |
| Exceptional items | 0.00 | 0.00 | 15.00 | 0.00 | -11.00 |
| Profit before tax | 279.00 | 447.00 | 485.00 | 460.00 | 331.00 |
| Current tax | 78.00 | 114.00 | 117.00 | 120.00 | 136.00 |
| Deferred tax | -4.00 | 0.00 | 2.00 | 4.00 | -44.00 |
| Tax expense | 74.00 | 114.00 | 119.00 | 124.00 | 92.00 |
| Profit for the period | 205.00 | 344.00 | 366.00 | 336.00 | 242.00 |
| Profit attributable to owners | 201.00 | 333.00 | 336.00 | 310.00 | 241.00 |
| Profit attributable to non-controlling interests | 4.00 | 11.00 | 29.00 | 26.00 | 1.00 |
| Other comprehensive income | -0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| Total comprehensive income | 205.00 | 344.00 | 367.00 | 336.00 | 242.00 |
| Earnings per share, basic | 26.87 | 41.88 | 42.03 | 38.75 | 6.03 |
| Earnings per share, diluted | 26.20 | 41.88 | 42.03 | 38.75 | 6.03 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|
| Total assets | 2,694.00 | 2,941.00 | 3,419.00 | 3,852.00 | 4,579.00 | 6,625.00 | 7,759.00 |
| Non-current assets | 2,140.00 | 2,464.00 | 2,859.00 | 3,259.00 | 3,954.00 | 5,746.00 | 6,821.00 |
| Current assets | 554.00 | 478.00 | 560.00 | 593.00 | 625.00 | 879.00 | 937.00 |
| Property, plant and equipment | 1,392.00 | 1,381.00 | 1,233.00 | 1,730.00 | 1,847.00 | 3,502.00 | 4,186.00 |
| Capital work-in-progress | 126.00 | 477.00 | 638.00 | 600.00 | 854.00 | 573.00 | 606.00 |
| Goodwill | 308.00 | 308.00 | 308.00 | 308.00 | 379.00 | 339.00 | 339.00 |
| Other intangible assets | 80.00 | 78.00 | 386.00 | 65.00 | 406.00 | 802.00 | 57.00 |
| Inventories | 45.00 | 43.00 | 50.00 | 49.00 | 54.00 | 80.00 | 97.00 |
| Trade receivables | 207.00 | 253.00 | 266.00 | 294.00 | 388.00 | 484.00 | 554.00 |
| Cash and cash equivalents | 101.00 | 62.00 | 38.00 | 47.00 | 63.00 | 81.00 | 55.00 |
| Total equity and liabilities | 2,694.00 | 2,941.00 | 3,419.00 | 3,852.00 | 4,579.00 | 6,625.00 | 7,759.00 |
| Equity | 1,853.00 | 1,938.00 | 2,085.00 | 2,093.00 | 2,283.00 | 2,576.00 | 2,558.00 |
| Equity share capital | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 |
| Other equity | 1,486.00 | 1,590.00 | 1,733.00 | 1,748.00 | 1,922.00 | 2,190.00 | 2,167.00 |
| Total liabilities | 841.00 | 1,003.00 | 1,334.00 | 1,759.00 | 2,296.00 | 4,049.00 | 5,200.00 |
| Non-current liabilities | 508.00 | 707.00 | 974.00 | 1,306.00 | 1,638.00 | 2,904.00 | 3,961.00 |
| Current liabilities | 333.00 | 296.00 | 360.00 | 452.00 | 658.00 | 1,146.00 | 1,239.00 |
| Borrowings, non-current | 436.00 | 634.00 | 901.00 | 1,226.00 | 1,560.00 | 2,670.00 | 2,673.00 |
| Borrowings, current | 40.00 | 45.00 | 54.00 | 129.00 | 222.00 | 517.00 | 571.00 |
| Trade payables | 199.00 | 174.00 | 206.00 | 197.00 | 271.00 | 329.00 | 323.00 |
Cash flow, as filed
| Line | 2022-03-31 | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 520.00 | 386.00 | 432.00 | 271.00 | 521.00 | 246.00 | 288.00 | 511.00 |
| Net cash from investing activities | -606.00 | -345.00 | -616.00 | -370.00 | -753.00 | -470.00 | -720.00 | -1,452.00 |
| Net cash from financing activities | 60.00 | -96.00 | 88.00 | 75.00 | 217.00 | 239.00 | 457.00 | 940.00 |
| Purchase of property, plant and equipment | 170.00 | 171.00 | 526.00 | 285.00 | 647.00 | 375.00 | 753.00 | 1,428.00 |
| Net increase in cash | -26.00 | -55.00 | -95.00 | -24.00 | -15.00 | 16.00 | 25.00 | -1.00 |
| con:CFO.BEFORE_TAX | 520.00 | 441.00 | 530.00 | 344.00 | 661.00 | 314.00 | 364.00 | 662.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | -2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 0.00 | 55.00 | 95.00 | 73.00 | 140.00 | 68.00 | 76.00 | 151.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 3.00 | 0.00 | 1.00 | 2.00 | 14.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 121.00 | 216.00 | 0.00 | 75.00 | 115.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 323.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-19 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 38.84 | 38.84 | 38.82 | 38.82 | 38.82 | 38.82 | 38.82 | 38.82 | 34.11 | 0.34 | 0.34 | 0.34 | 0.33 | 0.33 |
| Domestic institutions | 35.77 | 34.80 | 34.23 | 33.13 | 32.12 | 32.30 | 32.05 | 31.95 | 31.66 | 0.32 | 0.33 | 0.33 | 0.35 | 0.34 |
| Mutual funds | — | — | — | — | — | — | — | 25.35 | 25.25 | 0.27 | 0.28 | 0.27 | 0.29 | 0.29 |
| Insurance companies | 5.63 | 5.13 | 4.27 | 5.61 | 5.59 | 6.19 | 5.73 | 6.20 | 6.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Foreign institutions | 13.15 | 14.25 | 15.27 | 16.73 | 17.84 | 15.85 | 15.68 | 15.45 | 15.54 | 0.15 | 0.14 | 0.15 | 0.14 | 0.15 |
| Public | 61.16 | 61.16 | 61.18 | 61.18 | 61.18 | 61.18 | 61.18 | 61.18 | 65.89 | 0.66 | 0.66 | 0.66 | 0.68 | 0.68 |
| Non-institutional | 12.24 | 12.11 | 11.68 | 11.32 | 11.22 | 13.03 | 13.45 | 13.78 | 18.69 | 0.19 | 0.19 | 0.19 | 0.18 | 0.18 |
| Shares outstanding | 80027787 | 80027787 | 80027787 | 80027787 | 80027787 | 400138935 | 400138935 | 400138935 | 400138935 | 400138935 | 400138935 | 400138935 | 420006484 | 420006484 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| KIMS Hospital private Limited | Subsidairies | Any other transaction | 27,064,040,000.00 | 6 |
| Chalasani Hospital private Limited | Subsidairies | Any other transaction, Investment, Loan | 2,306,220,000.00 | 6 |
| KIMS Hospital Bengaluru private Limited | Subsidairies | Any other transaction, Interest received, Investment | 2,266,220,000.00 | 14 |
| KIMS Swastha Private Limited | Subsidairies | Any other transaction, Loan | 852,280,000.00 | 4 |
| Sarvejana Healthcare Private Limited | Subsidairies | Any other transaction, Investment, Purchase of goods | 597,880,000.00 | 8 |
| Kims Manavata Hospital Private Limited | Subsidairies | Any other transaction, Loan | 196,760,000.00 | 4 |
| KIMS Hospital Private Limited | Subsidairies | Any other transaction, Investment, Loan | 110,220,000.00 | 6 |
| Arunodaya Hospitals private Limited | Subsidairies | Any other transaction, Loan, Sale of goods or servic | 109,640,000.00 | 6 |
| Spanv Medisearch Lifesciences Private Limited | Subsidairies | Any other transaction, Interest received, Loan, Sale | 89,300,000.00 | 14 |
| KIMS Hospitals Kurnool Private Limited | Subsidairies | Any other transaction, Loan, Sale of goods or servic | 60,820,000.00 | 12 |
| Dr. B Bhaskar Rao | Key Management personnel | Any other transaction, Remuneration | 59,940,000.00 | 6 |
| KIMS Hospital Enterprises Private Limited | Subsidairies | Any other transaction, Purchase of goods or services | 58,060,000.00 | 6 |
| Iconkrishi Institute of Medical Sciences Private Limited | Subsidairies | Any other transaction, Interest received, Loan, Purc | 24,240,000.00 | 10 |
| Savera Institute of Medical Sciences Private Limited | Subsidairies | Any other transaction, Loan, Purchase of goods or se | 24,200,000.00 | 10 |
| Mr B Abhinay | Key Management personnel | Remuneration | 21,160,000.00 | 2 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-08 | Q1FY27 | KIMS BANGALORE CLUSTER, KIMS HOSPITALS, MANAGING DIRECTOR, KIMS HOSPITALS | Read the call |
| 2026-05-22 | Q4FY26 | KIMS HOSPITALS, MANAGING DIRECTOR, KIMS HOSPITALS | Read the call |
| 2026-02-13 | Q3FY26 | KIMS BANGALORE CLUSTER, KIMS HOSPITAL, STRATEGY AND M&A | Read the call |
| 2025-11-14 | Q2FY26 | OFFICER – KIMS HOSPITAL | Read the call |
| 2025-08-13 | Q1FY26 | KIMS HOSPITAL | Read the call |
| 2025-02-13 | Q3FY25 | KIMS BANGALORE CLUSTER, OFFICER- KIMS HOSPITAL | Read the call |
| 2024-08-14 | Q1FY25 | KIMS HOSPITAL | Read the call |
| 2024-05-23 | Q4FY24 | KIMS HOSPITAL | Read the call |
| 2024-02-08 | Q3FY24 | Read the call | |
| 2023-11-10 | Q2FY24 | BHASKAR, BOLLINENI, FOUNDER & | Read the call |
| 2023-08-11 | Q1FY24 | KIMS HOSPITAL, Kingsway, Nagpur. | Read the call |
| 2023-05-25 | Q4FY23 | BHASKAR, BOLLINENI, FOUNDER & | Read the call |
| 2023-02-15 | Q3FY23 | CHIEF, KIMS HOSPITALS, VIKAS | Read the call |
| 2022-11-17 | Q2FY23 | Read the call | |
| 2022-08-18 | Q1FY23 | CHIEF EXECUTIVE OFFICER, MANAGING DIRECTOR | Read the call |
| 2022-05-24 | Q4FY22 | CHIEF EXECUTIVE OFFICER, MANAGING DIRECTOR | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q3FY23 | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | This Rs.300 Crores NCD proposal is the proposal which we have taken is the enabling provision because to raise the funds through NCD you need to have … | So, Nasik, the slide 28 mentions 300 beds, INR250 crores of capex, right? | — | So in the previous presentations, previous quarter's presentations, the kind of capex we have given for Bangalore, it seems like these are asset-light… | Last question on the bookkeeping, so how much is on a ALOS for Q4 and how much is the operating bed currently you have and also can you give a capex n… | Which are our legacy assets, which is Nellore, Rajahmundry and Srikakulam and all three of them we are in fact doubling capacity there but one we have… | So, I think, consistently given the high occupancy in a few of the hospitals in AP, we are working towards reducing the ALOS especially till we get th… | So, just any thoughts on the kind of CAPEX we are planning and what are the timelines? |
| Capital allocation | Chennai at this point the Greenfield project has been put on hold but we are looking at some acquisition opportunities nothing concrete yet but yes if… | — | Since the acquisition, how has this unit fared? | — | So, there is a two clarity right now in terms of brownfield acquisition which we are pursuing is Bangalore and Nashik. | — | But what we are still exploring and we are seeing positive traction is on the O&M contracts with the commitment to buyback over a period of time. | So, there are one, two small acquisition opportunities that can potentially come up over the next two quarters, but they are not significantly big. |
| Costs | — | — | — | — | — | — | I believe there were some rental cost savings that were to commensurate after the new facility opening up. | — |
| Debt and cash | We are generating something like Rs.400 Crores of the internal cash every year and you should take the view of the three years because the company is … | — | — | I just wanted to know the net debt position as of December 31? | — | So you should assume that run rate of at around Rs.6 Crores per quarter, so Rs.24 Crores is the run rate which we should assume for that interest rate… | — | But the idea is now that the debt has reached its peak, close to INR 3,000 plus crores, the idea is we retire some debt and use the cash flow to do mo… |
| Demand | As far as Secunderabad is concerned there is headroom for growth; however, we are in the pipeline of finalizing or adding an incremental 300 to 400 be… | KIMS Hospital February 05, 2024 What are your thoughts on whether that is the supply-demand mismatch in a city like Nashik or some other cities that y… | Or you think that there is enough demand for, let's say, 3 or 4 large players to coexist in that micro market? | NABH and Thane is in pipeline, it will take some more time. | — | — | After that, we also plan to add few more beds in the Nagpur, which will be pipeline once this one -- after this year is over. | — |
| Guidance | There are two ongoing projects right now which is Bengaluru and Nashik and we expect on those two projects to spend at around Rs.250 Crores of the amo… | So, I just wanted to get an idea about what is the debt guidance and what is the current debt levels. | But if I think of, let's say, at maturity, what kind of ARPOB should we expect for Nashik? | And just want to understand, I believe your discussion or negotiation with insurance companies took a little longer than what we anticipated. | So, can you a give guidance related these facilities, how you are looking at? | In this role he would be providing strategic guidance and advice to the Royal College from India. | The good thing is Sunshine is increasing as we expected and shows a good track. | That is the guidance we would like to give. |
| Margin | Got your point and now my second question was related Kingsway so Kingsway we are at very initial stages if I exclude the one off we are at almost at … | And because of the decline in revenue, operating leverage has played out. | I see a sharp decline in the EBITDA margins here. | Is it possible for the management to provide the occupancy number for Thane as well as two Bangalore assets and also the trajectory for the EBITDA los… | Then going greenfield in Karnataka, Tamil Naidu and looking at acquisition opportunities in Central India and we still continue to wanting to do the s… | Consolidated EBITDA pre Ind-AS and other income grew by 38.8% on a year-on-year basis and 8.3% on a quarter-on-quarter basis to Rs.1563.3 million. | That's why the EBITDA has gone -- from 32% has gone down because of this INR10 crores has been spent. | Consolidated EBITDA pre-Ind AS is INR 131 crore, a decline of 33.5% and 32.3% on year-on- year and quarter-on-quarter basis respectively. |
| People | — | So, in Andhra Pradesh, our utilization is around 79%. | So, if we see for the current quarter because of the fresh hiring, I think the corporate overheads have gone up. | — | — | That is how it has been, so the attrition we have controlled any attrition, we have controlled any exists of the doctors other than the three people w… | Secunderabad, the doctors engagement hiring was a bit delayed because they are committed, but the other parent unit people didn't allow them to leave,… | May 18, 2026 come up, I guess there are some tangible attrition from the incumbents, etc. So, what, according to you, is helping to retain the talent … |
| Pricing | All of this will enable us to attract more clinical talent so we have identified the requirement of close to 20 clinicians that have to be joining Beg… | Is it going to be more pricing led or do you think that the mix can change in the coming two, three years? | There is a price hike because of insurance renewals. | So it's a little bit of everything, case mix, pricing and the payer mix. | — | — | May 17, 2024 Pricing might not recur every year, but you will still have a 2% to 4% pricing benefit and the other is mix. | And there are, I think, some concerns on pricing, et cetera. |
| Revenue growth | We add a little more the percentage has come down because the topline has been increased because of the Sunshine and Kingsway that is why the percenta… | If you look at the revenue growth in both the markets have been healthy as far as the year-on- year growth is concerned. | — | Q3 FY 26 Financial Highlights-Consolidated: Consolidated revenue from operations INR998 crores, a growth of 29.2% on year-on- year and 3.9% on a qua… | Right and sir broadly revenue growth organic and inorganic and the total blended growth rate. | — | And more so in AP, given that a lot of the capacity addition will come into play by Q3 and by Q4 of this financial year, we will see a strong rebound … | May 18, 2026 FY '26 highlights: Total revenue of INR 3,931 crore, a growth of 28.2% on year-on-year basis. EBITDA of INR 828 crore, a growth of 1.… |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2023-02-15 | Q3FY23 | VIKAS | There are two ongoing projects right now which is Bengaluru and Nashik and we expect on those two projects to spend at around Rs.250 Crores of the amount 250 plus some gastro projects and other equipment, etc., which is going on so it should be at around totaling to Rs.75 Crores so that is the amount which we are looking at Rs.325 Crores to Rs.350 Crores is the capex this year. |
| 2023-02-15 | Q3FY23 | VIKAS | Sagar as far as the AP acquired assets are concerned they are delivering something like that 20% of the margin and we expect those margins to grow to the AP matured trajectory in next 12 to 18 months time as the revenue grows up and we do the rationalization in terms of the addition of these facilities and the payments both. |
| 2023-05-25 | Q4FY23 | BOLLINENI | Once we move to that hospital in six months we should be able to bring in 10 clinicians and once that 10 to 15 clinicians join we will see an incremental revenue of 7-8 Crores of revenue, which will then change the EBITDA margin profile of the Begumpet facility likewise when the balance doctor in Gachibowli join they will also change the EBITDA profile of that hospital. |
| 2023-08-11 | Q1FY24 | KIMS HOSPITAL | By the end of the financial year, we should see at least 60%- 70% of the doctor on-boarding to be completed. |
| 2024-05-23 | Q4FY24 | KIMS HOSPITAL | This year, we are able to achieve -- this month, we are able to achieve INR18 crores of revenue and 20%, as we expected, the EBITDA growth is there. |